This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
A recent analysis of information from the Surveillance Epidemiology and End Results (SEER) database showed that patients who had surgery to remove small kidney tumors (tumors that are less than 1.5 inches across) have the same risk of dying of kidney cancer over a five-year period as those who received surveillance instead. Surveillance of kidney cancer involves using imaging tests, such as magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT or CAT) scans to watch for signs that the cancer is growing or worsening.
A recent analysis showed that early-stage, but aggressive (grows and spreads quickly) prostate cancer is more likely to be detected in black men and men older than 75. Generally, the percentage of men with this type of prostate cancer is very small (about 1 man out of 8,000 men develops this type of prostate cancer). Because this stage of prostate cancer causes no symptoms and cannot be felt during a physical exam or seen on imaging tests, it is only detected through prostate specific antigen (PSA) testing. PSA is a substance in the blood that is primarily made by the prostate gland. It can be found in higher-than-normal levels in men with various prostate conditions, including prostate cancer, benign (noncancerous) prostatic hyperplasia (BPH, an enlarged prostate), and inflammation or infection of the prostate.
In a new study, researchers found that patients with high-risk prostate cancer who received hormone therapy for 18 months lived as long as patients who received hormone therapy for 36 months. Androgens (male sex hormones), such as testosterone, help prostate cancer grow. Hormone therapy, also called androgen blockade therapy or androgen deprivation therapy, slows the growth of prostate cancer by lowering the levels of androgens or blocking the androgens from getting to the prostate cancer cell. It is a standard treatment for prostate cancer. However, long-term hormone therapy causes many side effects, such as hot flashes, loss of libido (sex drive), erectile dysfunction, weight gain, loss of bone density and muscle mass, and depression that worsen during the length of treatment. With this study, researchers hoped that a shorter course of hormone therapy would help treat the cancer equally well while reducing the side effects.